Skip to main content
. Author manuscript; available in PMC: 2020 May 18.
Published in final edited form as: Eur J Cancer Care (Engl). 2016 Jan 18;26(3):10.1111/ecc.12437. doi: 10.1111/ecc.12437

Figure 1.

Figure 1

A – Probability of symptom occurrence for each of the latent classes for the 25 symptoms on the Memorial Symptom Assessment Scale that occurred in ≥40% of the total sample (n=760) at Time 1 (i.e., Prior to next dose of chemotherapy).

B - Probability of symptom occurrence for each of the latent classes for the 25 symptoms on the Memorial Symptom Assessment Scale that occurred in ≥40% of the total sample (n=760) at Time 2 (i.e., Following next dose of chemotherapy).